Patients with GCB DLBCL demonstrated a lowered mutation frequency, whereas patients with non-GCB DLBCL exhibited a mutant status of MYD88 in 27.8% of cases. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.